• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
TRVI

TRVI

Trevi Therapeutics, Inc.

NASDAQHealthcareBiotechnologyUS

USD13.45

-0.05 (-0.37%)

Rating:C

Company Profile

CEO

Jennifer L. Good

IPO Date

2019-05-07

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$13.49

Prev. Close

$13.50

Day Low

$13.25

Day High

$13.56

52W Low

$5.41

52W High

$16.12

Market Cap

$1.91B

Volume

0.70M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

17.7%

Avg Negative

2.8%

Avg Neutral

79.4%

News Feed

Trevi Therapeutics to Present at 2021 BIO Digital Conference

PRNewsWire·6/9/2021·↑ positive

Trevi Therapeutics' (TRVI) CEO Jennifer Good on Q1 2021 Results - Earnings Call Transcript

Seeking Alpha·5/14/2021·↓ negative

Trevi Therapeutics to Report Q1 2021 Financial Results on May 13

PRNewsWire·5/6/2021·↑ positive

Trevi Therapeutics to Present at 20th Annual Needham Virtual Healthcare Conference

GlobeNewsWire·4/7/2021·↑ positive

Trevi Therapeutics, Inc. (TRVI) CEO Jennifer Good on Q4 2020 Results - Earnings Call Transcript

Seeking Alpha·3/25/2021·↓ negative

Trevi Therapeutics Announces Fourth Quarter and Year End 2020 Financial Results and Business Updates

GlobeNewsWire·3/25/2021·↑ positive

Trevi Therapeutics to Report Q4 and Year End 2020 Financial Results on March 25

GlobeNewsWire·3/18/2021·↓ negative

Trevi Therapeutics' (TRVI) Shares March Higher, Can It Continue?

Zacks Investment Research·2/3/2021·↑ positive

Trevi Therapeutics Appoints William Forbes, Pharm.D. as Chief Development Officer

GlobeNewsWire·2/1/2021·↑ positive

Trevi Therapeutics Announces Third Quarter 2020 Financial Results and Business Update

GlobeNewsWire·11/11/2020·↑ positive